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Patients with deep vein thrombosis or pulmonary embolism are recommended to receive anticoagulation for acute
treatment and secondary prevention of venous thromboembolism (VTE). Fast-acting direct oral anticoagulants,
with or without parenteral heparin, have the potential to replace vitamin K antagonists in this setting. Rivaroxaban,
a direct Factor Xa inhibitor, is approved in the European Union and the United States for the single-drug treatment
of deep vein thrombosis and pulmonary embolism and the secondary prevention of recurrent VTE in adults. The
approved rivaroxaban dose schedule (15 mg twice daily for 3 weeks followed by 20 mg once daily) was derived
based on pharmacological data from the clinical development programme to achieve a strong antithrombotic
effect in the acute treatment phase and address the need to balance efficacy and bleeding risk for long-term treatment
with a once-daily dose in the maintenance phase. Data from dose-ranging studies, pharmacokinetic modelling and
randomised phase III trials support the use of this regimen. Other direct oral anticoagulants have also shown favourable
efficacy and safety compared with standard treatment, and apixaban (European Union) and dabigatran (European
Union and United States) have been approved in this indication. There are practical aspects to rivaroxaban use that
must be considered, such as treatment of patients with renal and hepatic impairment, drug–drug interactions, monitoring
of effect and management of bleeding. This review discusses the derivation of the VTE treatment regimen for rivaroxaban,
summarises the clinical data for rivaroxaban and other direct oral anticoagulants in VTE treatment, and considers the
practical aspects of rivaroxaban use in this setting.
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Guidelines recommend that patients with deep vein
thrombosis (DVT) or pulmonary embolism (PE) should
receive anticoagulant treatment, starting with parenteral
induction using an agent such as unfractionated heparin
(UFH), low molecular weight heparin (LMWH) or fon-
daparinux [1,2]. The parenteral anticoagulant is then
overlapped with an oral vitamin K antagonist (VKA; e.g.
warfarin) until the latter has reached its target anticoa-
gulation level, after which the parenteral agent is discon-
tinued. VKA therapy is continued for as long as the risk
of recurrent venous thromboembolism (VTE) outweighs
the risk of bleeding [1,2]. This approach is effective if
managed well but does present challenges, both in theCorrespondence: harder@em.uni-frankfurt.de
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unless otherwise stated.acute phase of treatment, when two drugs must be ad-
ministered together, and over the course of long-term
therapy, because of the well-documented limitations of
VKAs. The latter include a slow onset and offset of ac-
tion, multiple drug and food interactions, and variable
responses, which necessitate frequent coagulation moni-
toring and dose adjustments [3].
Fast-acting, single-target, direct oral anticoagulants
with more predictable pharmacological properties than
VKAs and fewer drug interactions, and that do not require
routine coagulation monitoring, have been developed.
Four of these anticoagulants (rivaroxaban, apixaban, edox-
aban and dabigatran) have been tested against standard
therapy in randomised, controlled clinical studies for the
treatment of acute VTE and secondary prevention, either
alone or after parenteral induction [4-11]. Rivaroxaban, a
direct Factor Xa inhibitor, is approved in the Europeanhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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of DVT and PE and the secondary prevention of recurrent
VTE in adults. Apixaban, a direct Factor Xa inhibitor, and
dabigatran, a direct thrombin inhibitor, are also approved
for VTE treatment in the European Union, and dabigatran
is also licensed in this indication in the United States.
The approved dose regimen for rivaroxaban in VTE
treatment is 15 mg twice daily for the first 3 weeks, and
20 mg once daily thereafter for the specified duration of
therapy [12,13]. This schedule was derived based on the
fundamental pharmacological properties of rivaroxaban,
data from phase II dose-finding studies [14,15], pharmaco-
kinetic modelling [16] and randomised phase III clinical
trials [4,5]. This review article summarises the pharmaco-
logical and clinical rationale for the single-drug dose regi-
men of rivaroxaban for VTE treatment, including practical
considerations derived from the kinetic and dynamic
properties of rivaroxaban.
Fundamental aspects of rivaroxaban pharmacology
Rivaroxaban is an orally administered anticoagulant
that disrupts the action of Factor Xa by selectively but
reversibly binding to its active site (dissociation con-
stant of inhibitor [Ki] 0.4 nM) [17,18]. Inhibition by
rivaroxaban occurs whether Factor Xa is freely circu-
lating in plasma, bound in a clot or located in the
prothrombinase complex [17,19]. However, rivaroxa-
ban has no significant effect on the activity of pre-existing
thrombin molecules [18].
A summary of pharmacokinetic information for rivar-
oxaban and other direct oral anticoagulants is given in
Table 1 [20-25]. Rivaroxaban has high oral bioavailability
(80–100% for a 10 mg dose [12]) and is absorbed
rapidly, with maximum plasma concentration (Cmax)
reached between 2 and 4 hours and maximum Factor Xa













tmax (h) 2.0–4.0 1.0
t½ (h) 5–13 8–
Elimination 36% unchanged via active renal secretion;
30% renal excretion of inactive metabolites;
34% hepatobiliary (7% unchanged)
~2
~7
Metabolism CYP3A4, CYP2J2 and CYP-independent
mechanisms; P-gp substrate
CY
CYP, cytochrome P450; P-gp, P-glycoprotein; t½, half-life; tmax, time to maximum cophase I study, suppression of thrombin generation and
inhibition of coagulation was evident at 24 hours post-
dose (Figure 1) [18,27,28].
Overall, rivaroxaban showed predictable pharmaco-
kinetic and pharmacodynamic properties [18,26], and
a half-life of 5–9 hours in young, healthy subjects and
11–13 hours in elderly subjects [12] (Table 1). No signifi-
cant accumulation of rivaroxaban occurred with multiple
doses in healthy adults [26]. Age, sex and body weight did
not affect rivaroxaban clearance to a clinically relevant
extent [29,30], and no significant effect of Caucasian,
African-American, Hispanic, Japanese or Chinese ethnicity
was noted [12,31,32]. Under fasting conditions, exposure
was linear and proportional to dose for the 2.5 mg and
10 mg tablets, but at higher doses increases in Cmax and
area under the concentration–time curve (AUC) were
dose-proportional but non-linear [33]. Linear dose propor-
tionality was restored by taking the 15 mg and 20 mg
tablets with food [12].
Two-thirds of a rivaroxaban dose undergoes metabolic
degradation and is excreted in approximately equal pro-
portions via the hepatobiliary route and by the kidneys
[12,20] without evidence of any major or pharmacologic-
ally active metabolites circulating in plasma [20]. Meta-
bolic breakdown occurs via cytochrome P450 (CYP) 3A4
and CYP2J2, as well as by CYP-independent mecha-
nisms; rivaroxaban is also a substrate of P-glycoprotein
(P-gp) [12,25]. One-third of the rivaroxaban dose is
eliminated in the urine as unchanged drug via active
renal secretion [12,20].
Given the dual renal/metabolic elimination profile of
rivaroxaban, renal impairment and the presence of drugs
that inhibit metabolic degradation are the main factors that
can reduce rivaroxaban clearance and increase exposure.
The practical implications of this are further discussed




















P3A4; P-gp substrate CYP3A4; P-gp substrate P-gp substrate
ncentration.
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Figure 1 Effect of rivaroxaban 5 mg and 30 mg, and placebo, on thrombin generation. (A) ETP peak after activation by collagen (5 μg/ml),
(B) ETP peak after activation by tissue factor (1.4 nmol). Data are mean relative change from baseline ± standard deviation. The difference between
treatments was assessed in this study using the area under the time–effect profile curve; both rivaroxaban doses were significantly different from
placebo, but not significantly different from each other. Reproduced with permission from Graff J et al. [28]. ETP, endogenous thrombin potential.
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ance [CrCl] 30–49 ml/min) and severe (CrCl <30 ml/min)
renal impairment was increased by 1.5-fold and 1.6-fold,
respectively [34], and this led to increased pharmaco-
dynamic activity (Factor Xa inhibition). The overall effect
of moderate or severe renal impairment on rivaroxaban
pharmacokinetics was considered to be moderate. There
are no data for patients with CrCl <15 ml/min [12]. Ex-
posure was increased to a clinically relevant degree in
healthy subjects when rivaroxaban was co-administered
with strong inhibitors of both CYP3A4 and P-gp, specific-
ally the human immunodeficiency virus (HIV) protease
inhibitor ritonavir and the azole-antimycotic ketoconazole,
although drugs that were weaker inhibitors of both path-
ways, or strong inhibitors of only one, had a lesser effect
[25]. The anticoagulants enoxaparin and warfarin have
been shown to have no relevant effect on the pharmaco-
kinetics of rivaroxaban, but an additive pharmacodynamic
effect on Factor Xa inhibition was observed [35,36].
Rivaroxaban plasma concentrations were similar in
healthy subjects and those with mild hepatic impairment
(Child–Pugh A), but moderate impairment (Child–Pugh B)
led to increases in AUC of 2.27-fold and in Cmax of
1.27-fold [37]. Enhanced inhibition of Factor Xa activity
was evident in these subjects [37], meaning that a clinic-
ally relevant increase in bleeding risk would be expected
in patients with moderate hepatic impairment [12].
Derivation of a rivaroxaban dose schedule for
venous thromboembolism treatment
Clinical and pharmacological considerations
Data from phase III clinical studies of other anticoagulants
for VTE treatment suggest that the risk of recurrent VTE
is highest during the period following an initial event. Intwo randomised, phase III studies of acute VTE treatment
with the direct thrombin inhibitor ximelagatran and the in-
direct Factor Xa inhibitor idraparinux, a high risk of recur-
rent venous thromboembolic events was evident in the first
4 weeks after randomisation [38,39]. Therefore, if a single
oral agent is to replace the standard dual-drug approach, it
must exert a rapid effect. In healthy subjects, a 10 mg oral
dose of rivaroxaban had a similarly quick onset of action
to 40 mg subcutaneous enoxaparin, with peak Factor Xa
inhibition occurring for both drugs approximately 3 hours
after administration (corresponding to the expected time
of rivaroxaban Cmax), indicating that rivaroxaban would be
appropriate from the start of therapy without the need for
parenteral bridging (Figure 2) [35].
For long-term treatment, the predictable pharmaco-
kinetic and pharmacodynamic profiles of rivaroxaban
across patient populations, as well as a lack of food re-
strictions and relatively few drug interactions, contrast
with the variable pharmacology of VKAs and provide
the opportunity to employ fixed doses without the
need for routine coagulation monitoring [3]. Further-
more, because the pharmacodynamic effects and in-
hibition of thrombin generation remained evident
24 hours after dosing in phase I studies [18,28], once-
daily schedules for rivaroxaban are feasible. Recent
data from an analysis of United States healthcare
claims show that once-daily regimens for VTE treatment
are associated with better adherence to therapy than
twice-daily dosing schedules [40].
Determination of the rivaroxaban dose schedule in the
acute treatment phase
Rivaroxaban was initially evaluated in the phase II, Oral
Direct Factor Xa Inhibitor BAY 59–7939 in Patients
Figure 2 Anti-Factor Xa activity after administration of oral
rivaroxaban and subcutaneous enoxaparin alone and in
combination. Rivaroxaban 10 mg, enoxaparin 40 mg. Median values
in healthy subjects. Reproduced with permission from Kubitza D
et al. [35].
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DVT) dose-finding study [14]. Adult patients with
ultrasound-confirmed acute DVT but without PE were
randomised to receive rivaroxaban or the LMWH
enoxaparin 1 mg/kg twice daily for at least 5 days plus
dose-adjusted VKA (either warfarin, phenprocoumon
or acenocoumarol) for 12 weeks. Rivaroxaban was
dosed at 10, 20 or 30 mg twice daily, or 40 mg once
daily. The primary efficacy outcome was the propor-
tion of patients with an improvement in thrombotic
burden, which was defined as a reduction in the
thrombus score of at least four points evaluated by
ultrasound, without confirmed, symptomatic worsen-
ing or recurrence of DVT, confirmed symptomatic PE
or VTE-related death, at a mean 21 days from the start
of treatment (range 18–26 days). The principal safety
outcome was the incidence of major bleeding occur-
ring during the 12-week treatment period or up to
2 days after the last anticoagulant dose [14].
For the primary efficacy endpoint, 45.9% of patients
who received enoxaparin/VKA had an improvement
in thrombotic burden, compared with 53.0%, 59.2%,
56.9% and 43.8% of patients who received rivaroxaban
10, 20 and 30 mg twice daily, and 40 mg once daily,
respectively. Major bleeding did not occur in any pa-
tients treated with enoxaparin/VKA but was recorded
in 1.7%, 1.7%, 3.3% and 1.7%, respectively, of rivaroxa-
ban recipients [14]. Overall, the rivaroxaban twice-
daily doses appeared to offer a greater antithrombotic
effect than standard therapy in the acute phase, at
the cost of a small increase in major bleeding that was
lowest with the rivaroxaban 10 mg and 20 mg twice-
daily doses.Determination of the rivaroxaban dose schedule for
long-term treatment
A second, longer-term phase II dose-finding study
(EINSTEIN DVT) was also conducted to evaluate the
3-month efficacy and safety of several rivaroxaban doses
against enoxaparin/VKA for the prevention of recurrent
VTE in patients with confirmed DVT [15]. Patients were
randomised to receive rivaroxaban 20, 30 or 40 mg once
daily, or 5 days of heparin (UFH or a LMWH [tinzaparin
or enoxaparin]) followed by a VKA (warfarin, phenpro-
coumon, acenocoumarol or fluindione). Treatment was
given for 12 weeks. The primary efficacy outcome was the
incidence of the composite of symptomatic recurrent
DVT, symptomatic fatal or non-fatal PE, and asymptom-
atic deterioration in thrombotic burden (detected by ultra-
sound and perfusion lung scanning) at Day 84. The
principal safety outcome was the incidence of major plus
non-major clinically relevant bleeding occurring up to
2 days after the last anticoagulant dose [15].
The primary efficacy outcome occurred in 6.1%, 5.4%
and 6.6% of patients who received rivaroxaban 20, 30
and 40 mg once daily, respectively, compared with 9.9%
of patients who received standard therapy. Major or
non-major clinically relevant bleeding occurred in 5.9%,
6.0% and 2.2% of patients receiving rivaroxaban, respect-
ively, and in 8.8% of those given standard therapy [15].
There were three cases of major bleeding in the rivarox-
aban group and two in the standard therapy group.
Based on these outcomes, antithrombotic efficacy with a
20 mg once-daily dose appeared similar to that of the
higher doses tested and provided similar efficacy and
slightly lower rates of major or non-major clinically rele-
vant bleeding compared with standard therapy [15].
Pharmacokinetic validation of the rivaroxaban
dose regimen
Based on these phase II studies, a rivaroxaban dose regi-
men of 15 mg twice daily for the first 3 weeks, followed
by 20 mg once daily for the remainder of treatment, was
proposed for further investigation in phase III studies.
This schedule was expected to balance the need for a
strong antithrombotic effect in the acute phase, taking
into account the risk of bleeding, with the lowest
effective once-daily dose for long-term secondary
prevention [14,15].
Data were collected from patients who took part in
the two phase II studies in order to create a population-
based model of the pharmacokinetics of rivaroxaban in
patients with acute DVT [16]. A total of 4634 rivaroxa-
ban plasma samples from 870 patients were collected
and input into the model, which was based on previous
parameters used for healthy subjects and patients under-
going hip or knee replacement surgery [41-43]. The
model showed that the pharmacokinetics of rivaroxaban
Figure 4 Simulated plasma concentrations of rivaroxaban with
the venous thromboembolism treatment regimen*. Reproduced
with permission from Mueck W et al. [16]. bid, twice daily; od, once
daily. *15 mg bid for 3 weeks, followed by 20 mg od.
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tested (total daily doses of 20–60 mg), and the overall
variability between individuals was moderate and con-
sistent over the 12 weeks of treatment [16].
Variations in age and renal function affected rivaroxa-
ban pharmacokinetics in an anticipated manner, but
other demographic factors, such as age and sex, had a
minimal effect. When the model was used to simulate
plasma rivaroxaban concentration–time profiles after a
20 mg once-daily dose in patients who would be ex-
pected to be at high risk of recurrent VTE and/or bleed-
ing, older age and renal impairment had a moderate
effect on rivaroxaban exposure, whereas the influence of
low body weight was small. Rivaroxaban Cmax remained
within the range of the mean values for the overall
population, suggesting that dose reduction would not be
necessary in these vulnerable patients (Figure 3) [16].
As in healthy volunteers [41], the Cmax of rivaroxaban
was reached between 2 and 4 hours after dosing, regard-
less of once- or twice-daily administration [16]. Com-
pared with twice-daily dosing, once-daily rivaroxaban
doses led to a higher Cmax and a lower trough concen-
tration, but the differences were not significant based on
the 95% confidence level. Simulation of the proposed
rivaroxaban VTE treatment regimen (15 mg twice daily
for 3 weeks followed by 20 mg once daily) indicated no
substantial fluctuation in Cmax during the transition
from twice-daily to once-daily dosing (Figure 4) [16].Figure 3 Predicted plasma rivaroxaban concentration–time
profiles. ‘Typical’ patients and those with extremes of age, renal
function and body weight receiving rivaroxaban 20 mg once daily.
Reproduced with permission from Mueck W et al. [16]. CLCR, creatinine
clearance.Randomised phase III studies of rivaroxaban for
treatment of venous thromboembolism
The proposed rivaroxaban VTE treatment dose schedule
was taken forward to the phase III EINSTEIN programme,
which comprised three randomised clinical studies. Two
acute treatment trials, EINSTEIN DVT and EINSTEIN PE
[4,5], were complemented by a third study of extended
treatment, EINSTEIN EXT [4]. In total, 8282 patients
were randomised in EINSTEIN DVT and EINSTEIN PE
and a further 1197 were involved in EINSTEIN EXT.
Overall, the proportion of patients with unprovoked VTE
was reflective of that seen in clinical practice (approxi-
mately 63% in EINSTEIN DVT and EINSTEIN PE and
74% in EINSTEIN EXT). Among those with known risk
factors for VTE, previous VTE (~19%), recent surgery or
trauma (~18%) and immobilisation (~16%) were import-
ant in EINSTEIN DVT and EINSTEIN PE; previous VTE
(~16%) and immobilisation (~14%) were also prominent
characteristics in EINSTEIN EXT. There was a small but
relevant proportion of patients with active cancer in all
studies (~5%) [4,5].
EINSTEIN DVT and EINSTEIN PE followed the same
study design: patients were randomised to receive either
rivaroxaban 15 mg twice daily for 3 weeks, followed by
20 mg once daily, or enoxaparin 1 mg/kg twice daily
overlapping with dose-adjusted VKA (warfarin or aceno-
coumarol) [4,5]. For the latter, enoxaparin was discontin-
ued after a minimum of 5 days once the international
normalised ratio (INR) remained within the target range
of 2.0–3.0 for at least 2 days, as per guidelines [1,2].
EINSTEIN DVT recruited patients with symptomatic,
acute DVT confirmed by imaging, but excluded patients
who had PE [4]. Conversely, patients included in
EINSTEIN PE had confirmed PE with or without DVT
[5]; patients with PE who were haemodynamically
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according to guidelines [1,2], were excluded. Treatment
was continued for 3, 6 or 12 months based on clinical
evaluation of each patient’s risk of recurrent VTE and
bleeding. The primary efficacy outcome in both studies
was the incidence of symptomatic, recurrent VTE, and
the principal safety outcome was major plus non-major
clinically relevant bleeding [4,5].
In both EINSTEIN DVT and EINSTEIN PE, single-
drug rivaroxaban was non-inferior to dual-drug standard
therapy for the prevention of recurrent VTE (p < 0.001
and p = 0.003, respectively, for non-inferiority) (Table 2),
with a similar incidence of clinically relevant bleeding
[4,5]. Notably, in EINSTEIN PE, there was a 51% relative
risk reduction (RRR) in the incidence of major bleeding
compared with the enoxaparin/VKA arm [5]. In a
pooled analysis of the overall VTE population from the
two studies, rivaroxaban remained non-inferior to stand-
ard therapy for efficacy and was associated with a signifi-
cant 46% RRR in the incidence of major bleeding [44].
This led to a 33% relative risk improvement in net clin-
ical benefit (the composite of VTE and major bleeding)
with rivaroxaban compared with enoxaparin/VKA [44].
The greater patient numbers afforded by pooling the
data also allowed for a more detailed investigation of
important patient subgroups that are at increased risk
of recurrent VTE and/or bleeding. These included fra-
gile patients (those who were aged >75 years or had
CrCl <50 ml/min or body weight ≤50 kg), patients with
cancer and those with previous VTE. Rivaroxaban
remained non-inferior to standard therapy in these patient
groups with a consistent safety profile, and led to a signifi-
cant 73% RRR in major bleeding in fragile patients [44].
EINSTEIN DVT and EINSTEIN PE are notable
among phase III trials of direct oral anticoagulants for
acute VTE because patients with PE were investigated
in a separate study. The rationale for this was the
distinct nature and potential severity of PE compared
with DVT alone.
There is still a debate regarding the optimal duration
of anticoagulant treatment to prevent recurrent VTE.
Extended treatment with rivaroxaban has been com-
pared with placebo for the secondary prevention of VTE
(Table 3). The double-blind EINSTEIN EXT study en-
rolled patients who had completed 6–12 months of suc-
cessful anticoagulation with rivaroxaban or standard
therapy and for whom the decision whether to continue
or stop anticoagulation was uncertain [4]. Patients re-
ceived rivaroxaban 20 mg once daily or matched placebo
for a further 6 or 12 months. At the end of extended
treatment, rivaroxaban was superior to placebo for the
prevention of recurrent VTE (1.3% vs. 7.1%; p < 0.001)
and led to a non-significant increase in major bleeding
(four events with rivaroxaban vs. none with placebo;p = 0.11) [4]. To investigate further the use of rivaroxaban
in long-term secondary prevention, the three-arm EIN-
STEIN CHOICE study will compare a reduced dose of
rivaroxaban (10 mg once daily) with a standard dose
(20 mg once daily) and with aspirin (100 mg/day) in
patients with confirmed symptomatic DVT or PE who
have previously completed 6 or 12 months of anticoagu-
lant treatment (NCT02064439).
Randomised phase III studies of other direct oral
anticoagulants for treatment of venous
thromboembolism
Phase III studies of the direct Factor Xa inhibitors apixa-
ban and edoxaban, and the direct thrombin inhibitor
dabigatran, all enrolled mixed VTE populations. As with
rivaroxaban, apixaban was investigated as a single-drug
approach for the treatment of DVT and/or PE in the
AMPLIFY study, in which patients were randomised to
apixaban 10 mg twice daily for 7 days followed by 5 mg
twice daily, or standard enoxaparin/warfarin therapy, for
a fixed treatment duration of 6 months (Table 2) [6].
Apixaban was non-inferior to standard therapy for
the prevention of recurrent VTE (p < 0.001 for non-
inferiority) and led to significant reductions in major
bleeding (69% RRR) and clinically relevant bleeding (52%
RRR). Edoxaban and dabigatran were tested against
standard therapy in the Hokusai-VTE and RE-COVER
studies, respectively, but, unlike rivaroxaban and apixa-
ban, they were investigated as part of a dual-drug regimen
with initial parenteral anticoagulation (Table 2). Edoxaban
was given at a dose of 60 mg once daily (or 30 mg once
daily in patients with a CrCl of 30–50 ml/min, a body
weight of ≤60 kg or in the case of concomitant treatment
with strong P-gp inhibitors). Patients received treatment for
between 3 and 12 months based on clinical judgement and
patient preference [7]. In RE-COVER and RE-COVER II,
dabigatran was given at a fixed 150 mg twice-daily dose
and the treatment duration was fixed at 6 months [8,9].
Both edoxaban and dabigatran were non-inferior to VKA
after parenteral induction in these trials (p < 0.001 for
non-inferiority), with significant reductions in clinically
relevant bleeding and similar rates of major bleeding
to conventional treatment [7-9]. Dabigatran is now ap-
proved for VTE treatment in the European Union and
United States.
Extended treatment with apixaban and dabigatran has
also been compared with placebo for the secondary pre-
vention of VTE (Table 3). The AMPLIFY-EXT study
compared extended apixaban (2.5 mg or 5 mg twice
daily) with placebo in patients who had completed be-
tween 6 and 12 months of anticoagulation [10]. After
12 months of further treatment, apixaban was superior
to placebo for the prevention of VTE (p < 0.001 for both
apixaban doses) and led to a minimal rate of major
Table 2 Summary of phase III studies of direct oral anticoagulants for the acute treatment of VTE [4-9]
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Clinically relevant bleeding defined as the composite of major and non-major clinically relevant bleeding. a30 mg once daily in patients with creatinine
clearance 30–50 ml/min or body weight ≤60 kg or in patients receiving concomitant potent P-glycoprotein inhibitors; bSimilar outcomes reported in
RE-COVER II (data not shown).
bid, twice daily; DVT, deep vein thrombosis; HR, hazard ratio; INR, international normalised ratio; N/S, not specified; od, once daily; PE, pulmonary embolism;
RR, relative risk; VKA, vitamin K antagonist; VTE, venous thromboembolism.
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that it was compared both against placebo (RE-
SONATE) and against warfarin (RE-MEDY) for 6 months
of extended treatment in patients who had alreadyreceived at least 3 months’ anticoagulation [11]. Dabigatran
was superior to placebo (p < 0.001) and equivalent to
warfarin (p = 0.01 for non-inferiority) for long-term VTE
prevention, and was associated with non-significant
Table 3 Summary of phase III studies of direct oral anticoagulants for long-term prevention of recurrent VTE [4,10,11]











20 mg od for
a further 6 or
12 months
Placebo Recurrent VTE: rivaroxaban
superior to placebo





(6.0% vs. 1.2%; HR = 5.19;
p < 0.001)
Major bleeding: similar
incidence (0.7% vs. 0%;










5 mg bid for a
further
12 months
Placebo Recurrent VTE: apixaban
superior to placebo
(3.8% and 4.2% vs. 11.6%;
RR = 0.33 and 0.36;
p < 0.001 for both doses)
Clinically relevant bleeding:
similar incidence (3.2% and
4.3% vs. 2.7%; RR = 1.20
and RR = 1.62; p = N/S)
Major bleeding: similar
incidence (0.2% and 0.1% vs.





VTE already treated for







Placebo Recurrent VTE: dabigatran
superior to placebo





(5.3% vs. 1.8%; HR = 2.92;
p = 0.001)
Major bleeding: similar
incidence (0.3% vs. 0%;
HR N/A; p = 1.0)
Dabigatran RE-MEDY Patients with previous
VTE already treated for











(1.8% vs. 1.3%; HR = 1.44;
p = 0.01 for non-inferiority)
Clinically relevant bleeding:
significantly lower incidence
with dabigatran vs. warfarin





significant (0.9% vs. 1.8%;
HR = 0.52; p = 0.06)
bid, twice daily; HR, hazard ratio; INR, international normalised ratio; N/A, not applicable; N/S, not specified; od, once daily; RR, relative risk;
VTE, venous thromboembolism.
Harder Thrombosis Journal 2014, 12:22 Page 8 of 13
http://www.thrombosisjournal.com/content/12/1/22differences in the rates of major bleeding compared
with the comparator treatments. However, there was
a significant increase in acute coronary syndromes
with dabigatran compared with warfarin (0.9% vs.
0.2%; p = 0.02) [11].
Practical considerations with rivaroxaban
treatment for venous thromboembolism
Rivaroxaban enables acute treatment of DVT and PE
(provided the patient is haemodynamically stable) with-
out the need to induce rapid anticoagulation by use of a
parenteral agent [4,5]. This single-drug approach was
also tested successfully with apixaban [6], whereas dabi-
gatran and edoxaban were given after heparin in phase
III trials [7-9]. With rivaroxaban, the acute treatment
phase (15 mg twice daily for 21 days) is followed by once-
daily dosing (20 mg) for the prevention of VTE recur-
rence; this regimen can be continued for as long as judged
necessary (even indefinitely in those patients who need
lifelong anticoagulation) [12,13]. However, appropriatecommunication to primary care and other secondary care
providers with regard to the importance of timely transi-
tion from twice-daily to once-daily dosing after 3 weeks is
essential, as is regular patient contact and education on
the importance of correctly adhering to therapy. Ideally,
patients should receive a patient card with key information
both for them and for healthcare providers. Each manu-
facturer has their own patient card, whereas an example
generic card was suggested in the European Heart Rhythm
Association practical guide to direct oral anticoagulants
(available to download at www.NOACforAF.eu) [45]. Al-
though the guide refers to management of patients with
atrial fibrillation, the suggested card can be adapted to
other thromboembolic indications for which direct oral
anticoagulants may be prescribed.
In general, patients in need of anticoagulation after
VTE are younger and have fewer co-morbidities than
patients with atrial fibrillation [16]. However, label re-
strictions apply in case of impaired renal or hepatic
function and necessary co-medications. There are also
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treatment in this indication, derived from the pharmaco-
kinetic evaluation of rivaroxaban.
Co-morbidities
In patients with CrCl <50 ml/min, the initial rivaroxaban
dose of 15 mg twice daily needs no adjustment, and this
is also routinely the case for the 20 mg once-daily main-
tenance dose [12,13]. However, a reduction in the latter
to 15 mg once daily can be considered when the risk of
bleeding is judged to outweigh the risk of VTE, although
this advice applies only in the European Union and not
in the United States [12,13]. Circumstances in which re-
duction of the maintenance dose might be considered
include, for example, elderly, fragile patients or those re-
quiring additional platelet inhibition using aspirin. It
should, nevertheless, be noted that fragile patients in
the EINSTEIN DVT and EINSTEIN PE pooled analysis,
i.e. those who were elderly, had low body weight or
impaired renal function, had similar outcomes without
dose reduction compared with the overall patient popu-
lation, including a significant reduction in major bleed-
ing compared with standard therapy [44]. It should
furthermore be noted that rivaroxaban is currently not
recommended in children or adolescents (<18 years of
age) because of limited clinical data, and it should not
be used in pregnant or breastfeeding women [12,13]. A
study on the use of rivaroxaban in the treatment of VTE
in children and adolescents aged 6–17 years is ongoing
(EINSTEIN JUNIOR, NCT01684423).
In Europe, rivaroxaban is not recommended in pa-
tients with CrCl <15 ml/min (<30 ml/min in the United
States) or end-stage renal disease [12,13]. However, in
these cases, other oral anticoagulants are also not
permitted and choice of treatment is decided on a case-
by-case basis; in these patients, UFH treatment is often
initiated, followed by VKA [1,2]. Rivaroxaban is contra-
indicated in patients with hepatic disease associated with
coagulopathy and clinically relevant bleeding risk, in-
cluding cirrhotic patients classified as Child–Pugh B and
C [12,13]. Before initiating rivaroxaban, an appropriate
screen for clinical chemistry parameters, including hepatic
function, is necessary; in the opinion of this author, it seems
advisable to repeat the test in case of emergent co-
morbidities or if the treatment period exceeds 6 months.
Drug–drug interactions
Rivaroxaban is metabolised by several CYP450 enzymes
and is a substrate of CYP3A4 and P-gp [12,25]. The ex-
tent of any interaction between rivaroxaban and other
medications is greatly enhanced when a P-gp inhibitor
also has CYP450-inhibiting properties. Therefore, co-
administration of rivaroxaban with strong inhibitors of
both CYP3A4 and P-gp is not recommended [12,25];however, the agents concerned, such as systemic anti-
mycotics or some antiretroviral agents, are quite seldom
indicated in the ‘normal’ DVT patient population. Medica-
tions that are weaker inhibitors of both CYP3A4 and P-gp
or strong inhibitors of only one of these pathways have a
lesser effect on rivaroxaban pharmacology [12,25]. Strong
inducers of CYP3A4 (e.g. rifampicin or St John’s wort)
should be co-administered with caution. Furthermore, riv-
aroxaban should not be co-administered with dronedarone
owing to limited clinical data [12,13]. As with all direct
oral anticoagulants, co-administration with other anti-
coagulants is not recommended, and caution should be
used when non-steroidal anti-inflammatory drugs and
agents associated with an elevated risk of bleeding are
co-administered [12,13]. If indicated for coronary
artery disease, the use of aspirin at a dose not exceeding
100 mg/day may be combined with rivaroxaban [46],
although in patients with stable coronary artery disease,
rivaroxaban could be given alone without aspirin, decided
on a case-by-case basis [45]. A summary of co-medications
to be avoided during treatment with rivaroxaban, and those
that may be routinely co-administered or co-administered
with caution, is shown in Table 4 [12,13,25,47-50].
Switching from or to another anticoagulant
If a patient is receiving a VKA and has suboptimal INR
control, switching to rivaroxaban for treatment of VTE
or prevention of recurrence is possible by discontinuing
the VKA (irrespective of which one has been used) and
starting rivaroxaban when the INR is ≤2.5 [12,13]. There
are circumstances in which oral anticoagulation is not
possible or adequate in the emergency setting – for ex-
ample, when the patient is unable to swallow a tablet. In
this case, the rivaroxaban tablet may be crushed and
given through a gastric tube after confirmation that the
tube has been placed correctly [12]. Alternatively, initial
parenteral anticoagulation, preferably with LMWH, re-
mains appropriate for induction therapy. It is then
possible to switch to rivaroxaban by giving the first dose
0–2 hours before the next dose of LMWH or fondapari-
nux is scheduled; if UFH has been given as a continuous
infusion, the first rivaroxaban dose can be given immedi-
ately after termination of the infusion [12,13]. If the patient
is receiving rivaroxaban and parenteral anticoagulation with
LMWH becomes necessary (e.g. patient is unable to swal-
low), the first dose of the LMWH should be given at the
time the next rivaroxaban dose would have been scheduled.
If rivaroxaban needs to be replaced by another direct oral
anticoagulant, the first dose of the other oral agent should
be given at the time the next rivaroxaban dose would have
been scheduled. If transition from rivaroxaban to a VKA
becomes necessary, initiation of the VKA should be effected
as normal (loading dose) and rivaroxaban should be co-
administered with VKA until the INR is ≥2.0 [12,13]. The
Table 4 Summary of pharmacokinetic and pharmacodynamic drug interactions with rivaroxaban [12,13,25,47-50]






































aExcept when switching; bbased on a lack of clinical information.
HIV, human immunodeficiency virus; NSAID, non-steroidal anti-inflammatory drug.
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concentration to minimise interference by rivaroxaban-
mediated anticoagulation [51].
If emergency surgery is required in patients receiving
rivaroxaban, rivaroxaban should ideally be stopped at
least 24 hours before the intervention, taking into ac-
count the patient’s risk of bleeding against the potential
benefit of surgery [12]. Owing to its short half-life, rivar-
oxaban can be stopped closer to the time of surgery than
VKAs and can then be restarted when post-surgical
haemostasis is established. In contrast to VKAs, therapid onset of anticoagulant effect of rivaroxaban obvi-
ates any need for LMWH bridging [52].
Monitoring
In usual practice, and in common with the other direct
oral anticoagulants, rivaroxaban requires no routine
monitoring of its anticoagulant effect. However, clinical
experience with the new agents has shown that, in certain
situations, information about haemostatic status seems
valuable, e.g. when the patient is found unconscious, or
when a thrombotic or bleeding event is suspected and
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sidered. Other situations include cases of overdose when
the decline of effect or the efficacy of elimination mea-
sures needs to be observed, or when making decisions
about emergency surgery associated with a high risk of
bleeding. In some cases, adherence might also be assessed
by a coagulation test. Most laboratory tests are either spe-
cific (e.g. calibrated anti-Factor Xa chromogenic assays for
rivaroxaban from Diagnostica-Stago, Asnières-sur-Seine,
France; Hyphen-BioMed, Neuville-sur-Oise, France; and
Technoclone, Vienna, Austria) but not widely available, or
are readily available (e.g. prothrombin time or activated
partial thromboplastin time) but can provide only qualita-
tive information on overall coagulation [51]. If a specific
anti-Factor Xa chromogenic assay is used, expected trough
values (24 hours after last dose) for rivaroxaban with the
20 mg once-daily schedule are approximately 50 ng/ml,
whereas peak values 2–4 hours after tablet intake are
approximately 250 ng/ml (Figure 3) [16]. However, in-
terpretation of such results strongly relies on patient
characteristics and an exact knowledge of the dosing
history, and the results can be misleading when this in-
formation is lacking, for example in cases of impaired
patient consciousness. For qualitative measurement
(when an anti-Factor Xa assay is not available), the
prothrombin time has the best potential to reflect
rivaroxaban activity, but a certain therapeutic range
cannot be given. More importantly, reagents that are
sensitive to rivaroxaban should be used and the read-
ing must be made in seconds; it must not be converted
to an INR [52].
Management of bleeding
The relatively short half-life and the reversible inhibition
of Factor Xa by rivaroxaban (bypassing the need for new
synthesis of coagulation factors) mean that minor bleed-
ing can often be controlled by temporary or permanent
discontinuation of therapy. Recently published guidance
on emergency management of bleeding in patients re-
ceiving direct oral anticoagulants suggests routine sup-
portive care; activated charcoal may be considered if
ingestion was within approximately 2 hours prior to the
bleeding event [53-55]. The use of prothrombin complex
concentrate, activated prothrombin complex concentrate
or recombinant Factor VIIa is potentially useful [12,56].
Recently, modified recombinant Factor Xa has been
investigated as a potential reversal agent for Factor Xa in-
hibitors [57]. This protein lacks catalytic and membrane-
binding activity, but retains the ability to bind Factor Xa
inhibitors with subnanomolar affinity, and has the poten-
tial to be a universal reversal agent for small-molecule dir-
ect Factor Xa inhibitors and antithrombin-dependent
indirect Factor Xa inhibitors [58]. This agent is currently
undergoing a phase II clinical study in healthy volunteers(NCT01758432), but it is not expected to be commercially
available before 2016.
Administration
The rivaroxaban doses approved for the treatment of
VTE should be taken with a meal; tablets may be disin-
tegrated and mixed with food to facilitate swallowing
[12,13]. During the acute treatment phase (15 mg twice
daily), if the patient misses a morning dose, they should
be instructed to take this missing dose immediately (if
necessary at the same time as the later dose) to ensure the
required 30 mg total daily dose. A missed morning dose
during the maintenance phase (20 mg once daily) should
be taken within the day, but not added to the next day’s
dose [12,13].
Conclusions
Rivaroxaban has predictable pharmacokinetic properties
and exhibits rapid-onset, dose-proportional pharmaco-
dynamic effects that make it suitable for use as a single-
drug anticoagulant treatment for patients with VTE. The
approved rivaroxaban regimen for VTE treatment (15 mg
twice daily followed by 20 mg once daily) was derived based
on dose-finding studies and pharmacokinetic modelling,
and balances the need for a strong antithrombotic effect in
the acute phase of VTE treatment with a once-daily main-
tenance dose with a favourable benefit–risk profile. Clinical
data from randomised phase III studies support the use of
this regimen. Rivaroxaban is suitable for a wide range of
patients, but consideration should be given to renal and
hepatic function and co-medications, as well as other prac-
tical aspects, before and during treatment.
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